GLP-1 & Incretin Peptides

Survodutide (BI 456906) is an investigational once-weekly injectable peptide that activates both the glucagon and GLP-1 receptors; its strongest evidence comes from phase 3 randomized trials in obesity and fatty…

Yes. The FDA approved orforglipron, sold as Foundayo, on April 1, 2026 for chronic weight management in adults with obesity, or overweight plus at least one weight-related condition (FDA). In…

Mazdutide (LY3305677, IBI362) is a once-weekly injected peptide that activates both the GLP-1 and glucagon receptors, approved in China since 2025 and backed by phase 3 human trials. In the…

The Wegovy pill is oral semaglutide 25 mg, a once-daily tablet form of the GLP-1 peptide drug in Wegovy injections. In the OASIS 4 trial (Human RCT, n=307), adults with…

Nisotirostide (LY3457263) is an investigational once-weekly injectable peptide from Eli Lilly that selectively activates the NPY2 receptor, the receptor used by the gut hormone PYY. It is being developed as…

CagriSema is an investigational once-weekly injection that combines cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 receptor agonist; its strongest evidence is phase 3 randomized trials, including two pivotal…

Retatrutide is not FDA approved for any use. It is an investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors) from Eli Lilly, and its strongest evidence is a set…

Retatrutide (LY3437943) is an investigational synthetic peptide from Eli Lilly that activates the GIP, GLP-1 and glucagon receptors at once; its strongest evidence is phase 3 randomized trials in obesity…